NANJING PHARMACEUTICAL COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.91 CNY | +1.03% |
|
+2.94% | +1.45% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,437 | 4,875 | 4,635 | 5,114 | 6,709 | 6,342 |
| Enterprise Value (EV) 1 | 9,266 | 10,827 | 11,829 | 12,886 | 13,650 | 13,078 |
| P/E ratio | 16.4 x | 14.1 x | 12.3 x | 10.1 x | 10.8 x | 10.9 x |
| Yield | 2.35% | 2.14% | 2.47% | 2.44% | 2.73% | 3.31% |
| Capitalization / Revenue | 0.14 x | 0.13 x | 0.12 x | 0.11 x | 0.13 x | 0.12 x |
| EV / Revenue | 0.3 x | 0.29 x | 0.3 x | 0.29 x | 0.27 x | 0.24 x |
| EV / EBITDA | 10.6 x | 9.66 x | 10.3 x | 8.99 x | 8.96 x | 7.89 x |
| EV / FCF | -6.54 x | -10.9 x | -9.62 x | -38 x | 147 x | 3.78 x |
| FCF Yield | -15.3% | -9.2% | -10.4% | -2.63% | 0.68% | 26.5% |
| Price to Book | 1.21 x | 1.21 x | 1.09 x | 1.11 x | 1.12 x | 0.99 x |
| Nbr of stocks (in thousands) | 10,41,611 | 10,41,611 | 10,41,611 | 10,41,611 | 13,10,315 | 13,10,231 |
| Reference price 2 | 4.260 | 4.680 | 4.450 | 4.910 | 5.120 | 4.840 |
| Announcement Date | 29/03/19 | 31/03/20 | 26/03/21 | 25/03/22 | 30/03/23 | 07/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 31,303 | 37,156 | 39,817 | 45,123 | 50,222 | 53,590 |
| EBITDA 1 | 877.1 | 1,121 | 1,148 | 1,434 | 1,524 | 1,657 |
| EBIT 1 | 791.8 | 1,008 | 1,027 | 1,301 | 1,389 | 1,528 |
| Operating Margin | 2.53% | 2.71% | 2.58% | 2.88% | 2.77% | 2.85% |
| Earnings before Tax (EBT) 1 | 475.8 | 588.9 | 677.8 | 838.9 | 906 | 978.1 |
| Net income 1 | 264.3 | 346.9 | 376.4 | 505.2 | 595.7 | 577.8 |
| Net margin | 0.84% | 0.93% | 0.95% | 1.12% | 1.19% | 1.08% |
| EPS 2 | 0.2600 | 0.3330 | 0.3610 | 0.4850 | 0.4750 | 0.4450 |
| Free Cash Flow 1 | -1,417 | -995.6 | -1,230 | -338.7 | 92.72 | 3,464 |
| FCF margin | -4.53% | -2.68% | -3.09% | -0.75% | 0.18% | 6.46% |
| FCF Conversion (EBITDA) | - | - | - | - | 6.08% | 208.98% |
| FCF Conversion (Net income) | - | - | - | - | 15.56% | 599.41% |
| Dividend per Share 2 | 0.1000 | 0.1000 | 0.1100 | 0.1200 | 0.1400 | 0.1600 |
| Announcement Date | 29/03/19 | 31/03/20 | 26/03/21 | 25/03/22 | 30/03/23 | 07/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 4,829 | 5,952 | 7,194 | 7,772 | 6,941 | 6,737 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 5.506 x | 5.31 x | 6.267 x | 5.421 x | 4.555 x | 4.065 x |
| Free Cash Flow 1 | -1,417 | -996 | -1,230 | -339 | 92.7 | 3,464 |
| ROE (net income / shareholders' equity) | 9.35% | 10% | 10.1% | 12.1% | 12% | 10.2% |
| ROA (Net income/ Total Assets) | 2.74% | 3.03% | 2.83% | 3.3% | 3.02% | 3.18% |
| Assets 1 | 9,648 | 11,434 | 13,299 | 15,317 | 19,744 | 18,168 |
| Book Value Per Share 2 | 3.520 | 3.850 | 4.090 | 4.420 | 4.580 | 4.910 |
| Cash Flow per Share 2 | 2.170 | 2.020 | 1.420 | 2.010 | 1.780 | 1.810 |
| Capex 1 | 312 | 301 | 247 | 307 | 155 | 158 |
| Capex / Sales | 1% | 0.81% | 0.62% | 0.68% | 0.31% | 0.3% |
| Announcement Date | 29/03/19 | 31/03/20 | 26/03/21 | 25/03/22 | 30/03/23 | 07/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +1.45% | 893M | |
| +15.21% | 70.09B | |
| -2.19% | 24.01B | |
| +8.13% | 8.32B | |
| -18.28% | 8.23B | |
| 0.00% | 8.08B | |
| +19.12% | 4.41B | |
| 0.00% | 4.12B | |
| -2.82% | 3.88B | |
| +23.97% | 3.71B |
- Stock Market
- Equities
- 600713 Stock
- Financials NanJing Pharmaceutical Company Limited